Literature DB >> 18398029

Genetic polymorphisms involved in insulin-like growth factor (IGF) pathway in relation to mammographic breast density and IGF levels.

Caroline Diorio1, Jacques Brisson, Sylvie Bérubé, Michael Pollak.   

Abstract

The insulin-like growth factor (IGF) pathway is believed to play a role in carcinogenesis of the mammary gland. Single nucleotide polymorphisms (SNPs) of IGF-I, IGF-binding protein-3 (IGFBP-3), IGF receptor 1, insulin receptor substrate 1, and phosphoinositide-3-kinase, catalytic, beta polypeptide genes, which are members of the IGF pathway, have been associated with risk of common cancers, breast density, and/or IGF levels but results remain inconclusive. Thus, we evaluated the association of 11 targeted IGF pathway SNPs with circulating IGF levels and mammographic breast density. Among 741 white premenopausal women, blood samples were collected at time of screening mammography, and plasma IGF-I and IGFBP-3 levels were measured by ELISA. Percent and absolute breast density were estimated using a computer-assisted method. Multivariate linear models were used to examine the associations. Women carrying increasing number of copies of the rare allele of IGF-I rs1520220 and rs6220 SNPs had increased percent breast density (P(trend) = 0.04 and 0.06, respectively). Carriers of increasing number of copies of the rare allele of phosphoinositide-3-kinase, catalytic, beta polypeptide rs361072 SNP had decreased percent (P(trend) = 0.04) and absolute (P(trend) = 0.02) breast density. An association of insulin receptor substrate 1 rs1801278 SNP with absolute density (P(trend) = 0.03) was also observed. All four IGFBP-3 SNPs (including rs2854744) were associated with IGF-I and IGFBP-3 levels. This study shows that several components of the IGF pathway are associated with breast density or IGF levels. Our findings provide additional support for the idea that several components of the IGF pathway may affect breast cancer risk and that this effect on breast cancer development may be mediated, at least in part, through its influence on the morphogenesis of breast tissue.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18398029     DOI: 10.1158/1055-9965.EPI-07-2500

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  26 in total

1.  Insulin-like growth factor 1 gene polymorphism in women with breast cancer.

Authors:  Danylo Rafhael Costa-Silva; Maria da Conceição Barros-Oliveira; Rafael Soares Borges; Larysse Maira Campos-Verdes; João Paulo da Silva-Sampaio; Carla Solange Escorcio-Dourado; Luana Mota Martins; Airlane Pereira Alencar; Edmund Chada Baracat; Vladimir Costa Silva; Benedito Borges da Silva
Journal:  Med Oncol       Date:  2017-03-17       Impact factor: 3.064

2.  Prospective study of insulin-like growth factor-I, insulin-like growth factor-binding protein 3, genetic variants in the IGF1 and IGFBP3 genes and risk of coronary artery disease.

Authors:  Sally L Ricketts; Katrijn L Rensing; Jeff M Holly; Li Chen; Elizabeth H Young; Robert Luben; Sofie Ashford; Kijoung Song; Xin Yuan; Abbas Dehghan; Benjamin J Wright; Dawn M Waterworth; Vincent Mooser; Gérard Waeber; Peter Vollenweider; Stephen E Epstein; Mary S Burnett; Joseph M Devaney; Hakon H Hakonarson; Daniel J Rader; Muredach P Reilly; John Danesh; Simon G Thompson; Alison M Dunning; Cornelia M van Duijn; Nilesh J Samani; Ruth McPherson; Nicholas J Wareham; Kay-Tee Khaw; S Matthijs Boekholdt; Manjinder S Sandhu
Journal:  Int J Mol Epidemiol Genet       Date:  2011-08-03

3.  Mutational analysis of the insulin-like growth factor 1 receptor tyrosine kinase domain in non-small cell lung cancer patients.

Authors:  Kathy Gately; Lydia Forde; Stephen Gray; Derek Morris; Aidan Corvin; Prerna Tewari; Kenneth O'Byrne
Journal:  Mol Clin Oncol       Date:  2015-06-11

4.  Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients.

Authors:  Thomas Winder; Wu Zhang; Dongyun Yang; Yan Ning; Pierre Bohanes; Armin Gerger; Peter M Wilson; Alexandra Pohl; David J Mauro; Christiane Langer; Eric K Rowinsky; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2010-10-08       Impact factor: 12.531

5.  Genotypes and haplotypes in the insulin-like growth factors, their receptors and binding proteins in relation to plasma metabolic levels and mammographic density.

Authors:  Margarethe Biong; Inger T Gram; Ilene Brill; Fredrik Johansen; Hiroko K Solvang; Grethe I G Alnaes; Toril Fagerheim; Yngve Bremnes; Stephen J Chanock; Laurie Burdett; Meredith Yeager; Giske Ursin; Vessela N Kristensen
Journal:  BMC Med Genomics       Date:  2010-03-19       Impact factor: 3.063

6.  Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival.

Authors:  Mala Pande; Melissa L Bondy; Kim-Anh Do; Aysegul A Sahin; Jun Ying; Gordon B Mills; Patricia A Thompson; Abenaa M Brewster
Journal:  Breast Cancer Res Treat       Date:  2014-08-10       Impact factor: 4.872

Review 7.  Insulin receptor substrates (IRSs) and breast tumorigenesis.

Authors:  Bonita Tak-Yee Chan; Adrian V Lee
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-22       Impact factor: 2.673

Review 8.  IGF binding proteins (IGFBPs) and regulation of breast cancer biology.

Authors:  Claire M Perks; Jeff M P Holly
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-25       Impact factor: 2.673

Review 9.  Can genes for mammographic density inform cancer aetiology?

Authors:  Linda E Kelemen; Thomas A Sellers; Celine M Vachon
Journal:  Nat Rev Cancer       Date:  2008-09-05       Impact factor: 60.716

10.  Effect of insulin-like growth factor gene polymorphisms alone or in interaction with diabetes on the risk of pancreatic cancer.

Authors:  Hideo Suzuki; Yanan Li; Xiaoqun Dong; Manal M Hassan; James L Abbruzzese; Donghui Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-12       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.